1103535-60-9Relevant academic research and scientific papers
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease
Rudd, Michael T.,McCauley, John A.,Romano, Joseph J.,Butcher, John W.,Bush, Kimberly,McIntyre, Charles J.,Nguyen, Kevin T.,Gilbert, Kevin F.,Lyle, Terry A.,Holloway, M. Katharine,Wan, Bang-Lin,Vacca, Joseph P.,Summa, Vincenzo,Harper, Steven,Rowley, Michael,Carroll, Steven S.,Burlein, Christine,Dimuzio, Jillian M.,Gates, Adam,Graham, Donald J.,Huang, Qian,Ludmerer, Steven W.,McClain, Stephanie,McHale, Carolyn,Stahlhut, Mark,Fandozzi, Christine,Taylor, Anne,Trainor, Nicole,Olsen, David B.,Liverton, Nigel J.
, p. 7201 - 7206 (2013/01/15)
A series of macrocyclic compounds containing 2-substituted-quinoline moieties have been discovered and shown to exhibit excellent HCV NS3/4a genotype 3a and genotype 1b R155K mutant activity while maintaining the high rat liver exposure. Cyclization of the 2-substituted quinoline substituent led to a series of tricyclic P2 compounds which also display superb gt3a potency.
Macrocyclic Compounds As Antiviral Agents
-
, (2010/08/07)
A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. Formula (I):
